Literature DB >> 3928750

Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta.

G E Nedwin, L P Svedersky, T S Bringman, M A Palladino, D V Goeddel.   

Abstract

Human peripheral blood mononuclear cells (PBMC) were induced by recombinant interleukin 2 and mitogens to secrete two distinct cytotoxic polypeptides, tumor necrosis factor-alpha (TNF-alpha) and tumor necrosis factor-beta (TNF-beta), previously called lymphotoxin. Treatment of PBMC with recombinant human interleukin 2 (rIL 2) or mitogens in combination with recombinant human interferon-gamma (rIFN-gamma) resulted in augmented production of both TNF-alpha and TNF-beta. rIFN-gamma alone had no effect on production of either cytotoxic polypeptide. TNF-alpha was produced within 2 to 3 hr after induction and was the major cytotoxin produced by PBMC during the first 48 hr of culture, after which time TNF-beta became the predominant species. TNF-beta was first secreted into the media after 8 hr of induction. Enhanced levels of both TNF-alpha and TNF-beta were seen when the PBMC were separated into adherent and nonadherent cells. Both TNF-alpha and TNF-beta were induced in different tumor cell lines of hematopoietic origin. The results demonstrate that the production of TNF-alpha and TNF-beta can be enhanced by two lymphokines, IL 2 and IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928750

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  112 in total

Review 1.  Role of cytokines in testicular function.

Authors:  D B Hales; T Diemer; K H Hales
Journal:  Endocrine       Date:  1999-06       Impact factor: 3.633

2.  Oral aspirin and ibuprofen increase cytokine-induced synthesis of IL-1 beta and of tumour necrosis factor-alpha ex vivo.

Authors:  S Endres; R E Whitaker; R Ghorbani; S N Meydani; C A Dinarello
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

Review 3.  Polypeptides controlling hematopoietic cell development and activation. I. In vitro results.

Authors:  F Herrmann; R Mertelsmann
Journal:  Blut       Date:  1989-03

4.  Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor.

Authors:  H Vlassara; L Moldawer; B Chan
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

5.  Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients.

Authors:  J W Mier; G Vachino; J W van der Meer; R P Numerof; S Adams; J G Cannon; H A Bernheim; M B Atkins; D R Parkinson; C A Dinarello
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

6.  Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.

Authors:  B Brooks; R C Rees
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

7.  Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2.

Authors:  G A Limb; A Meager; J Woolley; M Wadhwa; J Biggerstaff; K A Brown; R A Wolstencroft
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

8.  Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.

Authors:  M Toledano; C Mathiot; J Michon; G Andreu; D Lando; M Brandely; W H Fridman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

9.  Regulatory T cell-like responses in deer mice persistently infected with Sin Nombre virus.

Authors:  Tony Schountz; Joseph Prescott; Ann C Cogswell; Lauren Oko; Katy Mirowsky-Garcia; Alejandra P Galvez; Brian Hjelle
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-17       Impact factor: 11.205

10.  Growth hormone activation of human monocytes for superoxide production but not tumor necrosis factor production, cell adherence, or action against Mycobacterium tuberculosis.

Authors:  J Warwick-Davies; D B Lowrie; P J Cole
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.